Clinical Trials | February 28, 2026
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Subscribe To Our Newsletter & Stay Updated
